Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Endocrinology ; 155(3): 703-15, 2014 Mar.
Article in English | MEDLINE | ID: mdl-24424057

ABSTRACT

IGF-1 and IGF-2 are potent mitogens acting through the IGF-1 receptor (IGF-1R). The importance of the IGF system in neoplasia has been demonstrated in several models, and IGF-1 signaling has become a target for drug development. The drug candidate BI 836845 is a fully human IgG1 ligand-neutralizing antibody that cross-reacts with IGF-1 and IGF-2. It has been shown to reduce both IGF-1R phosphorylation and cellular proliferation in preclinical studies. In rodent studies, administration of BI 836845 leads to large increases in total IGF-1 concentration in serum, despite reduced serum IGF-1 activity as measured by a kinase activation assay. Despite the fact that anti-IGF-ligand antibodies have entered clinical trials, their effect on IGF-binding proteins has not been described. In this report, we developed a novel technique to measure ligand-BI 836845 binding, and we apply it to a mouse model in various contexts. We show that although large increases in total serum IGF-1 levels are observed, the vast majority of ligand is present as a complex with BI 836845, and total serum IGF-binding protein-3 levels are decreased. Finally, we show that BI 836845 treatment induces an increase in GH levels, a finding consistent with attempted compensation at the level of the pituitary. Our results reveal complexities in the physiologic sequelae of BI 836845 administration that have implications for determination of optimal dosing regimens and for development of pharmacodynamic endpoints for clinical trials.


Subject(s)
Antibodies, Neutralizing/chemistry , Insulin-Like Growth Factor Binding Protein 3/chemistry , Insulin-Like Growth Factor II/chemistry , Insulin-Like Growth Factor I/chemistry , Animals , Antibodies, Monoclonal, Humanized , Antibodies, Neutralizing/pharmacology , Drug Evaluation, Preclinical , Enzyme-Linked Immunosorbent Assay , Humans , Immunoglobulin G/chemistry , Insulin-Like Growth Factor Binding Protein 3/blood , Ligands , Male , Mice , Mice, Inbred C57BL , Phosphorylation , Protein Binding , Receptor, IGF Type 1/chemistry
2.
Nanomedicine ; 9(7): 945-50, 2013 Oct.
Article in English | MEDLINE | ID: mdl-23563045

ABSTRACT

In order to investigate the effect of SWCNTs in the embryo, we examined the outcome of SWCNTs in avian embryo at an early stage of development. We found that SWCNTs-treatment inhibits the angiogenesis of the chorioallantoic membrane (CAM) and in the chicken embryo. Moreover, we showed that SWCNTs can harm the normal development of the embryo since all SWCNTs-exposed embryos are smaller in comparison with their matched controls. We also found that the majority of SWCNTs-exposed embryos die before 12days of incubation. Macroscopic examination did not reveal any anomalies in these embryos. However, RT-PCR analysis of eleven genes, which are important regulators of cell proliferation, apoptosis, survival and angiogenesis, shows that these genes are deregulated in brain and liver tissues from SWCNTs-treated embryos in comparison with their matched controls. This study suggests that SWCNTs could have a very toxic effect on the normal development of the embryo. FROM THE CLINICAL EDITOR: In this study, a significant toxicity of single-walled carbon nanotubes was observed during normal embryogenesis: the nanotubes inhibited the angiogenesis of the chorioallantoic membrane (CAM) in chicken embryos. All exposed embryos died before 12 days of incubation, suggesting a severe effect.


Subject(s)
Embryonic Development/drug effects , Nanotubes, Carbon/toxicity , Toxicity Tests , Animals , Chick Embryo , Chorioallantoic Membrane/blood supply , Chorioallantoic Membrane/drug effects , Gene Expression Regulation, Developmental/drug effects , Liver/cytology , Liver/drug effects , Liver/embryology , Neovascularization, Physiologic/drug effects
3.
J Biol Chem ; 286(19): 16567-73, 2011 May 13.
Article in English | MEDLINE | ID: mdl-21388950

ABSTRACT

A recent report (Zhong, D., Xiong, L., Liu, T., Liu, X., Liu, X., Chen, J., Sun, S. Y., Khuri, F. R., Zong, Y., Zhou, Q., and Zhou, W. (2009) J. Biol. Chem. 284, 23225-23233) details that 2-deoxy-D-glucose (2-DG), a well known inhibitor of glycolysis and a candidate antineoplastic agent, also induces insulin-like growth factor 1 receptor (IGF-1R) signaling through the inhibition of insulin-like growth factor 1-insulin-like growth factor-binding protein 3 (IGF-1-IGFBP-3) complex formation. Zhong et al. hypothesized that disrupted IGF-1/IGFBP-3 binding by 2-DG led to increased free IGF-1 concentrations and, consequently, activation of IGF-1R downstream pathways. Because their report suggests unprecedented off-target effects of 2-DG, this has profound implications for the fields of metabolism and oncology. Using ELISA, surface plasmon resonance, and novel "intensity-fading" mass spectrometry, we now provide a detailed characterization of complex formation between IGF-1 and IGFBP-3. All three of these independent methods demonstrated that there was no effect of glucose or 2-DG on the interaction between IGF-1 and IGFBP-3. Furthermore, we show examples of 2-DG exposure associated with reduced rather than increased IGF-1R and AKT activation, providing further evidence against a 2-DG increase in IGF-1R activation by IGF-1-IGFBP-3 complex disruption.


Subject(s)
Deoxyglucose/metabolism , Glucose/metabolism , Insulin-Like Growth Factor Binding Protein 3/metabolism , Insulin-Like Growth Factor I/metabolism , Cell Line, Tumor , Enzyme-Linked Immunosorbent Assay/methods , HeLa Cells , Humans , Kinetics , Mass Spectrometry/methods , Protein Binding , Protein Interaction Mapping/methods , Proto-Oncogene Proteins c-akt/metabolism , Receptor, IGF Type 1/metabolism , Surface Plasmon Resonance
4.
Growth Factors ; 28(4): 243-55, 2010 Aug.
Article in English | MEDLINE | ID: mdl-20370577

ABSTRACT

Insulin-like growth factor binding protein 2 (IGFBP-2) has been implicated in the pathophysiology of neoplasia. The PI3K/AKT/mTOR pathway has recently been shown to be a predominant regulator of IGFBP-2 at the protein level in MCF-7 breast cancer cells. However, there are gaps in knowledge with respect to the molecular mechanisms that underlie this regulation. Here, we show that the PI3K/AKT/mTOR pathway regulates IGFBP-2 protein levels by modulating IGFBP-2 mRNA abundance in MCF-7 cells. This change is achieved by regulating transcription through a critical region present in the first 200 bp upstream of the transcription initiation site where Sp1 transcription factor binds and drives transcription. IGF-1 treatment leads to increased nuclear abundance of Sp1 and increased IGFBP-2 mRNA and protein levels. Rapamycin and LY294002 induce a decline in Sp1 nuclear abundance and IGFBP-2 mRNA and protein levels. This work provides a mechanistic explanation for the observed effects of the PI3K/AKT/mTOR pathway on IGFBP-2 levels in MCF-7 cells.


Subject(s)
Insulin-Like Growth Factor Binding Protein 2/metabolism , Proto-Oncogene Proteins c-akt/metabolism , Sp1 Transcription Factor/metabolism , Blotting, Western , Cell Line, Tumor , Chromones/pharmacology , Electrophoresis, Polyacrylamide Gel , Enzyme-Linked Immunosorbent Assay , Fluorescent Antibody Technique , Gene Expression , Gene Expression Regulation , Humans , Insulin-Like Growth Factor Binding Protein 2/genetics , Intracellular Signaling Peptides and Proteins/metabolism , Morpholines/pharmacology , Neoplasms/metabolism , Phosphatidylinositol 3-Kinases/metabolism , Polymerase Chain Reaction , Promoter Regions, Genetic , Protein Kinases/metabolism , Protein Serine-Threonine Kinases/metabolism , Proto-Oncogene Proteins c-akt/genetics , RNA, Messenger/biosynthesis , RNA, Messenger/genetics , RNA, Messenger/metabolism , Signal Transduction , Sirolimus/pharmacology , Somatomedins , TOR Serine-Threonine Kinases/metabolism , Transcription, Genetic
5.
J Biol Chem ; 282(2): 1136-43, 2007 Jan 12.
Article in English | MEDLINE | ID: mdl-17092937

ABSTRACT

Many endocrine and neuroendocrine cells contain specialized secretory organelles called dense core secretory granules. These organelles are the repository of proteins and peptides that are secreted in a regulated manner when the cell receives a physiological stimulus. The targeting of proteins to these secretory granules is crucial for the generation of certain peptide hormones, including insulin and ACTH. Although previous work has demonstrated that proteins destined to a variety of cellular locations, including secretory granules, contain targeting sequences, no single consensus sequence for secretory granule-sorting signals has emerged. We have shown previously that alpha-helical domains in the C-terminal tail of the prohormone convertase PC1/3 play an important role in the ability of this region of the protein to direct secretory granule targeting (Jutras, I. Seidah, N. G., and Reudelhuber, T. L. (2000) J. Biol. Chem. 275, 40337-40343). In this study, we show that a variety of alpha-helical domains are capable of directing a heterologous secretory protein to granules. By testing a series of synthetic alpha-helices, we also demonstrate that the presence of charged (either positive or negative) amino acids spatially segregated from a hydrophobic patch in the alpha-helices of secretory proteins likely plays a critical role in the ability of these structures to direct secretory granule sorting.


Subject(s)
Neurosecretory Systems/metabolism , Protein Sorting Signals/physiology , Secretory Vesicles/chemistry , Secretory Vesicles/metabolism , Amino Acid Sequence , Animals , Cells, Cultured , Hormones/chemistry , Hormones/metabolism , Hydrophobic and Hydrophilic Interactions , Mice , Molecular Sequence Data , Neurosecretory Systems/cytology , Protein Structure, Secondary , Proteins/chemistry , Proteins/metabolism , Recombinant Fusion Proteins/chemistry , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...